Protect Pharmaceutical Corporation (PRTT)
ValueMarkers Composite Index
DCF data not available
Protect Pharmaceutical Corporation (PRTT) — VMCI valuation read
Protect Pharmaceutical Corporation (PRTT) carries a VMCI composite of 63/100, 13 points above the Industrials sector median of 50. Among mid-cap names, that gap places PRTT in the top third on the five-pillar weighting (Value 35%, Quality 30%, Integrity 15%, Growth 12%, Risk 8%).
The PRTT insider tape has been silent for the past 30 days on Form 4. Where executives neither buy nor sell, the bull and bear cases lean harder on filings cadence and the next earnings line.
**Investor frame.** Value reads PRTT trades at 22.0x earnings, 22% above the Industrials median of 18.0x, which compresses or extends through the 11.0x EV/EBITDA versus a Industrials 12.0x. Quality: ROIC of 14.0% sits 4.0pp above the Industrials median (10.0%). Risk: net debt to EBITDA of 0.3x leaves covenant headroom, the line to track on Protect Pharmaceutical Corporation's next 10-Q.
PRTT fell 2.8% over the trailing 7 days, with a -7.1% read on a 30-day basis.
Protect Pharmaceutical Corporation primarily focuses on crop farming and agricultural businesses. It acquires the Can Noguera property located in Selva Girona region in Spain. Its property consists of 60 hectares of arable land, 390 hectares of forests, 6 mineral and freshwater wells, and 3000 square meters of built properties. The company was formerly known as Pro-Tect, Inc. and changed its name to Protect Pharmaceutical Corporation in March 2010. Protect Pharmaceutical Corporation was founded in 1987 and is based in Las Vegas, Nevada.
Related Stocks in Industrials
Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.